OmniAb, Inc.

OABI Healthcare Biotechnology

OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024. In the quarter to June 2026, revenue grew 244.2%, EPS grew 66.7% and free cash flow grew 211.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.59 0.14 −2.96%
Market cap
$687.7M
P/E
0.0×
Fwd P/E
−6.1×
Dividend yield
—
F-score
2/9
Altman Z
2.45
Beneish M
−2.40
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 2 4

+8 more TTM periods

ROE
(16.95%) (20.25%) (23.36%) (22.37%)
ROA
(15.11%) (18.10%) (20.68%) (19.86%)
ROIC
(14.52%) (16.96%) (20.24%) (19.81%)
Return on Tangible Assets
(72.90%) (89.61%) (110.70%) (95.95%)
Average Days of Receivables
98.02 159.41 144.51 53.55
Free Cash Flow per Share
(0.14) (0.18) (0.30) (0.28)
Free Cash Flow
(18.14) (23.02) (34.02) (32.25)
Other line items

Show all line items

Columns are period end dates